Tari A. King, MD, Appointed Associate Chair for Multidisciplinary Oncology

Tari A. King, MD, has been appointed associate chair for Multidisciplinary Oncology in the Department of Surgery. Dr. King will both lead and enable innovative and efficient approaches to oncology patient care at Brigham Health and Dana-Farber Cancer Institute. She will be responsible for optimizing oncology care provided by Department of Surgery practitioners in areas such as patient access, ambulatory care and care coordination.

Tari A. King, MD

Tari A. King, MD
Associate Chair for Multidisciplinary Oncology, Department of Surgery, Brigham and Women’s Hospital
Chief, Breast Surgery, Dana-Farber/Brigham and Women’s Cancer Center
Associate Professor of Surgery, Harvard Medical School

Tari A. King, MD, is the chief of Breast Surgery at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), the associate division chief for Breast Surgery at Brigham and Women’s Hospital (BWH) and an associate professor of surgery at Harvard Medical School. She also directs the efforts of the Breast Cancer Personalized Risk assessment, Education and Prevention (B-PREP) Program at BWH. Dr. King received her medical degree from University of Colorado Health Sciences Center and completed a General Surgery Residency at Ochsner Clinic Foundation Hospital (now Ochsner Medical Center) in New Orleans. She completed both a Surgical Research Fellowship and a Breast Surgery Clinical Fellowship at Memorial Sloan Kettering Cancer Center.

Dr. King leads the clinical, research, and educational activities of the breast surgical service while also maintaining an active clinical practice devoted to the diagnosis and surgical treatment of breast cancer. Her clinical and research efforts focus on improving clinical management strategies for women at high risk of developing breast cancer with a special emphasis on lobular carcinoma in situ. She also has an interest in the role of surgery in Stage IV breast cancer and through the Translational Breast Cancer Research Consortium (TBCRC) she successfully initiated and completed accrual to a multi-center trial addressing this issue.

She has received several awards to support her work on the molecular genetics of lobular carcinoma in situ, including the Society of Surgical Oncology (SSO) Clinical Investigator Award in Breast Cancer Research (2008), a Career Catalyst Award (2009), an Investigator Initiated Research Award (2012) and a leadership grant from the Susan G. Komen for the Cure Foundation (2016). Dr. King currently serves on the Steering Committee for the TBCRC and the NCI Breast Oncology Local Disease Task Force and is the vice chair of the Quality Committee for the SSO.